{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:44:05Z","timestamp":1793454245846,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02912-y","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T09:02:16Z","timestamp":1723280536000},"page":"3832-3849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons"],"prefix":"10.1007","volume":"41","author":[{"given":"Walter","family":"Reinisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil Y.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Seidelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valencia","family":"Remple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani","family":"Wegrzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sanchez Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"2912_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11938-017-0120-8","volume":"15","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Sabol T, Vaziri H. Update on the use of biologic therapy in ulcerative colitis. Curr Treat Options Gastroenterol. 2017;15:155\u201367.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2912_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f432","volume":"346","author":"AC Ford","year":"2013","unstructured":"Ford AC, Moayyedi P, Hanauer SB. Ulcerative colitis. BMJ. 2013;346: f432.","journal-title":"BMJ"},{"key":"2912_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383.","journal-title":"Gastroenterology"},{"key":"2912_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ibd\/izad037","volume":"30","author":"X Lu","year":"2024","unstructured":"Lu X, Zhou Z-Y, Xin Y, et al. Matching-adjusted indirect comparisons of filgotinib vs vedolizumab, tofacitinib, and ustekinumab for moderately to severely active ulcerative colitis. Inflamm Bowel Dis. 2024;30:64\u201377.","journal-title":"Inflamm Bowel Dis"},{"key":"2912_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2021","unstructured":"Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2021;16:2\u201317.","journal-title":"J Crohns Colitis"},{"key":"2912_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450\u201361.","journal-title":"Gastroenterology"},{"key":"2912_CR7","doi-asserted-by":"crossref","unstructured":"Bencardino S, D'Amico F, Faggiani I, et al. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. Journal of clinical medicine. 2023; 12.","DOI":"10.3390\/jcm12155014"},{"key":"2912_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"2912_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"2912_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"2912_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Sharara AI, et al. Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status. Clin Gastroenterol Hepatol. 2022;20:591-601.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2912_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328.","journal-title":"Lancet"},{"key":"2912_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods."},{"key":"2912_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161\u201370.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2912_CR15","doi-asserted-by":"crossref","unstructured":"Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360. 2023; 5:otad009.","DOI":"10.1093\/crocol\/otad009"},{"key":"2912_CR16","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","volume":"71","author":"NE Burr","year":"2022","unstructured":"Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2022;71:1976\u201387.","journal-title":"Gut"},{"key":"2912_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165435","volume":"11","author":"AD Vickers","year":"2016","unstructured":"Vickers AD, Ainsworth C, Mody R, et al. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS ONE. 2016;11: e0165435.","journal-title":"PLoS ONE"},{"key":"2912_CR18","doi-asserted-by":"crossref","unstructured":"Attauabi M, Dahl EK, Burisch J, Gubatan J, Nielsen OH, Seidelin JB. Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. eClinicalMedicine. 2023; 57:101866.","DOI":"10.1016\/j.eclinm.2023.101866"},{"key":"2912_CR19","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s11096-018-0743-4","volume":"40","author":"C Trigo-Vicente","year":"2018","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, Garc\u00eda-L\u00f3pez S, L\u00f3pez-Del VA. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm. 2018;40:1411\u20139.","journal-title":"Int J Clin Pharm"},{"key":"2912_CR20","doi-asserted-by":"crossref","unstructured":"Welty M, Mesana L, Padhiar A, et al. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin. 2020; 36:595\u2013606.","DOI":"10.1080\/03007995.2020.1716701"},{"key":"2912_CR21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18:2179-91.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2912_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.14309\/ajg.0000000000002263","volume":"118","author":"D Ahuja","year":"2023","unstructured":"Ahuja D, Murad MH, Ma C, Jairath V, Singh S. Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Am J Gastroenterol. 2023;118:1618\u201325.","journal-title":"Am J Gastroenterol"},{"key":"2912_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health."},{"key":"2912_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials. Pharmacoeconomics. 2010;28:935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"2912_CR25","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"2912_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215\u201326.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02912-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02912-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02912-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:24:44Z","timestamp":1726244684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02912-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02912-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Walter Reinisch WR has served as a speaker for AbbVie, Celltrion, Ferring, Janssen, Galapagos Medice, MSD, Roche, Pfizer, Sobi, Takeda, as a consultant for AbbVie, Amgen, AOP Orphan, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celltrion, Eli Lilly, Galapagos, Gilead, Index Pharma, Janssen, Medahead, Microbiotica, Pfizer, Takeda; as an advisory board member for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galapagos, Janssen, Pfizer, and has received research funding from AbbVie, Janssen, Sandoz, Sanofi, Takeda. Gil Y. Melmed is a consultant for AbbVie, Arena, BI, BMS, Ferring, Fresenius Kalbi, Genentech, Gilead, Lilly, Janssen, Pfizer, Prometheus, Samsung Bioepis, Takeda, and Techlab. Hiroshi Nakase reports receiving personal fees from AbbVie Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Celgene K.K., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., D Daiichi Sankyo Co., Ltd JIMRO Co., Ltd., as well as grants for commissioned\/joint research from Hoya Group Pentax Medical, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd. Jakob Seidelin has received research grants from Takeda and Janssen, and is a national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. Christopher Ma has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Pendopharm, Pfizer, Prometheus Biosciences Inc., Roche, Sanofi, Takeda, Tillotts Pharma; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Organon, Pendopharm, Pfizer, Takeda; royalties from Springer Publishing; research support from Ferring, Pfizer. Si Xuan, Valencia Remple, Lani Wegrzyn, Gwen Levy, Yuri Sanchez Gonzalez are employees of AbbVie and may own stock or options. Jacinda Tran is a funded PhD student at the University of and was a contractor for AbbVie. Remo Panaccione has received support for consulting, speaker, advisory board member for, and\/or research\/educational support from: Abbott, AbbVie, Abbivax, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, Ventyx, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This analysis utilized de-identified data from published clinical trial data and therefore ethics committee approval was not required. Each individual trial included in this analysis was approved by independent ethics committees or institutional review boards at each study site and all patients provided written informed consent before enrolling in each clinical trial. Study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}